Tag: HEA MTC PHA BIO

Foresee’s Oral ALDH2 Activator, Mirivadelgat to Enter Clinical Testing in Parkinson’s Disease in the SLEIPNIR Phase 2a Platform Trial

TAIPEI, June 8, 2026 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that Foresee's oral ALDH2 activator, mirivadelgat, has been selected to enter clinical testing in...

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment...

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 7, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative...

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 8, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative...

Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval

NANJING, China, June 5, 2026 /PRNewswire/ -- NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors....

Mabwell’s 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease

SHANGHAI, June 4, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its independently developed innovative...

Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress

The intravenous part of the Phase IIb clinical dose-finding trial PROCEED met its primary endpoint, with bocunebart demonstrating a statistically significant reduction in monthly...

World’s First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory...

SAN FRANCISCO and SUZHOU, China, June 4, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and...

Demand for Compounding Pharmacies in USA to Reach USD 12.79 Billion by 2036 Amid Growing Need for Personalized Therapies and Specialized Medication Solutions

NEWARK, Del., June 2, 2026 /PRNewswire/ -- The Demand for Compounding Pharmacies in USA is projected to grow from USD 6.04 billion in 2026 to...

Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

Positive Results from Phase 2a Clinical TrialStudy met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumorsTrial revealed promising...

/C O R R E C T I O N — Ranok Therapeutics/

In the news release, Ranok Therapeutics Announces Positive Interim Phase 1 Data Of Its KRAS G12D Inhibitor RNK08954 In Patients With KRAS G12D-Mutated Metastatic...

Daewoong Therapeutics Microneedle Patch Achieves Best-in-Class Bioavailability, Proving the Strength of Its Drug-Delivery Platform

More than 80% relative bioavailability compared with injectable obesity therapy, well above the roughly 30% reported for existing microneedle patches and setting a new...

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

Entered into secured credit agreement with Innoviva for $15 million maturing in 2029 Announced positive topline results from the Phase 1b/2a diSArm trial for AP-SA02 LOS...

AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.

New $195 million facility will further enhance AbbVie's active pharmaceutical ingredient (API) production capacity and capabilities in the U.S.Expansion is part of AbbVie's previously announced commitment...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsHEA MTC PHA BIO

Datavault AI Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Minister MacDonald concludes G7 Agriculture Ministers’ Meeting

SRAD Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Sportradar Group AG Class Action Lawsuit

Tag: HEA MTC PHA BIO

Foresee’s Oral ALDH2 Activator, Mirivadelgat to Enter Clinical Testing in Parkinson’s Disease in the SLEIPNIR Phase 2a Platform Trial

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval

Mabwell’s 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease

Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress

World’s First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory...

Demand for Compounding Pharmacies in USA to Reach USD 12.79 Billion by 2036 Amid Growing Need for Personalized Therapies and Specialized Medication Solutions

Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

/C O R R E C T I O N — Ranok Therapeutics/

Daewoong Therapeutics Microneedle Patch Achieves Best-in-Class Bioavailability, Proving the Strength of Its Drug-Delivery Platform

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us